Skip to main content
. 2001 Aug;133(8):1213–1218. doi: 10.1038/sj.bjp.0704211

Figure 2.

Figure 2

Effects of the PAR-1 agonists on gastrointestinal transit in mice. The human PAR-1-derived peptide SFLLR-NH2 (SFp-NH2) or the control peptide FSLLR-NH2 (FSp-NH2) (a) and the specific PAR-1 agonist TFLLR-NH2 (TFp-NH2) (b), in combination with i.p. amastatin at 2.5 μmol kg−1, were administered i.p. to the mouse. Data represent the mean±s.e.mean from 8–10 (a) or 4–6 (b) mice.